June 14, 2024

1145-P: Development of MLX-0871, a Potent, Isoform-Selective, Orally Available AMPK Activator, Displays Efficacy in Obese and Type 2 Diabetes Models

Key Points

Key points are not available for this paper at this time.

Abstract

Introduction Biolexis Therapeutics, Inc. Stock/Shareholder; Arrien Pharmaceuticals. Board Member; Oncolexis Therapeutics, Inc. C. Lin: None. Z. Li: None. K. Medley: None. D.J. Bearss: Employee; BioLexis Therapeutics, Halia Therapeutics. Funding Biolexis Therapeutics, Inc.

Bookmark

1145-P: Development of MLX-0871, a Potent, Isoform-Selective, Orally Available AMPK Activator, Displays Efficacy in Obese and Type 2 Diabetes Models

Key Points

Abstract

Cite This Study

Also Consider

Also Consider